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Abstract
Background: Cardiac computed tomography (CT) is often performed in patients who are at high risk for lung
cancer in whom screening is currently recommended. We tested diagnostic ability and radiation exposure of a
novel ultra-low-dose CT protocol that allows concomitant coronary artery evaluation and lung screening.
Methods: We studied 30 current or former heavy smoker subjects with suspected or known coronary artery disease
who underwent CT assessment of both coronary arteries and thoracic area (Revolution CT, General Electric). A new
ultrafast-low-dose single protocol was used for ECG-gated helical acquisition of the heart and the whole chest. A
single IV iodine bolus (70–90 ml) was used. All patients with CT evidence of coronary stenosis underwent also
invasive coronary angiography.
Results: All the coronary segments were assessable in 28/30 (93%) patients. Only 8 coronary segments were not
assessable in 2 patients due to motion artefacts (assessability: 98%; 477/485 segments). In the assessable segments,
20/21 significant stenoses (> 70% reduction of vessel diameter) were correctly diagnosed. Pulmonary nodules were
detected in 5 patients, thus requiring to schedule follow-up surveillance CT thorax. Effective dose was 1.3 ± 0.9 mSv
(range: 0.8–3.2 mSv). Noteworthy, no contrast or radiation dose increment was required with the new protocol as
compared to conventional coronary CT protocol.
Conclusions: The novel ultrafast-low-dose CT protocol allows lung cancer screening at time of coronary artery
evaluation. The new approach might enhance the cost-effectiveness of coronary CT in heavy smokers with
suspected or known coronary artery disease.
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Background
Cardiac computed tomography (CT) scan is an ideal
diagnostic tool for identifying coronary artery disease in
patients with low or intermediate risk [1]. In recent
years, cardiac CT is being often performed in patients
who are at high risk either for coronary artery disease or
lung cancer. The update edition of the National Institute
for Health and Care Excellence (NICE) guidelines
recommends cardiac CT as the first-line diagnostic tool
for patients with new-onset chest pain due to suspected
CAD [2]. Also, symptomatic patients with known coron-
ary artery disease and previous percutaneous coronary
intervention who have an unclear stress test but whose
presentation suggests a high likelihood of having an in-
stent restenosis or a ‘de novo’ stenosis might benefit
from cardiac CT [3]. In 2014, the U.S. Preventive Ser-
vices Task Force recommended annual lung cancer
screening with ultra-low dose computed tomography for
current and former heavy smokers aged 55 to 80 years
[4]. Indeed, lung cancer screening in patients with
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suspected or known coronary artery disease undergoing
cardiac CT may provide the opportunity to implement
recommendation for lung cancer screening in clinical
practice [5].
The aim of this pilot study was to test the diagnostic
ability and radiation exposure of a novel ultra-low-dose
CT protocol that along with coronary artery evaluation
allows lung screening with no increase in contrast or ra-
diation dose. The new technique overcomes the limita-
tion of a double dose of contrast and radiation usually
needed to assess cardiac and lung regions during two
different examinations.
Methods
Study population
We studied 30 current or former heavy smokers aged 55
to 79 years. All were symptomatic subjects with effort-
induced or typical chest pain with suspected or known
coronary artery disease. Subjects were excluded in case
of contraindications to iodinated contrast such as aller-
gies and chronic kidney failure, or if there was any suspi-
cion of pregnancy (Table 1). All cases underwent cardiac
CT for assessment of coronary arteries. Additionally, all
individuals had CT scanning for early lung cancer detec-
tion. Invasive coronary angiography was performed sub-
sequently in all patients who had evidence of ≥ 1
coronary stenosis (> 70% reduction of vessel diameter).
The study conforms to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Institu-
tional Board Review Committee of our Institution (ID
Number: 671/2017/D). All participants gave their written
informed consent for the entire study, including radiation
exposure. The STARD (Standards for Reporting of Diag-
nostic Accuracy Studies) guidelines for reporting studies
of diagnostic accuracy were followed [6].
Study procedures
All subjects underwent simultaneous CT evaluation of
coronary arteries and thoracic area (Revolution CT,
General Electric, Boston, MA, US). The CT scanner
operates in prospectively ECG-triggered sequential scan-
ning mode, i.e. a tool adopted in spiral acquisitions in
order to optimize radiation dose by adjusting the x-ray
tube current. In case of heart rate > 70 beats/min, study
subjects were given 50 mg of metoprolol orally 2 h be-
fore CT examination. ECG-gated helical prospective ac-
quisition started from the carena to the apex of the
heart to evaluate coronary arteries (100 kVp, variable
mAs, thickness 0,625 mm, about 6 s apnea), followed by
fast, low dose acquisition, from pulmonary apex to the
bases, on the whole chest (100 to 120 kVp, auto mAs to
adapt to the patient BMI, thickness 1,25 mm, 3 s apnea)
(Fig. 1). A single IV iodine bolus (70–90 ml) was used. A
bolus of 1 mL/kg of body weight (minimum of 70 mL)
of iodixanol (Ultravist 370, Bayer HealthCare Pharma-
ceuticals, Berlin, Germany) followed by 80 mL of saline
solution was continuously injected into a right antecubi-
tal vein through a catheter using a 5 mL/s flow rate. The
segmental analysis of the coronary arteries was per-
formed using the classification proposed by the Ameri-
can Heart Association which takes into consideration 16
segments [7]. When present, the intermediate branch
(labeled as segment 17) was included in the analysis. In-
dependently of reference vessel size, a coronary stenosis
was considered significant if the diameter was ≥ 70%.
The evaluation of any coronary stenosis was carried out,
independently, by two investigators (FP and GP) who
were blinded to the patients’ clinical characteristics. Cor-
onary assessment was performed through a dedicated
Table 1 Inclusion and exclusion criteria of the study patients
INCLUSION CRITERIA
• Current or former heavy smoking habit
• Age: 55–79 years
• High risk of coronary artery disease
• Previous diagnosis of coronary artery disease
EXCLUSION CRITERIA
• Age < 40 years
• Diagnosis of acute coronary syndrome
• History of allergic reactions
• Irregular heart rate
• Chronic renal failure (i.e., estimated glomerular filtration
rate≤ 60 ml/min/1.73 m2)
• Microalbuminuria
• Lack of consent
Fig. 1 Ultrafast single protocol. The ECG-gated helical prospective
acquisition started from the carena to the apex of the heart to evaluate
coronary arteries (a, field of vew of cardiac scan), followed by fast, low
dose acquisition, from pulmonary apex to the bases, on the whole
chest (b, field of view of thoracic scan)
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workstation (Vitrea2 FX, Vital Images, Plymouth, MN,
USA) which allows the automatic identification of the
coronary arterial borders [8]. When data analysis could
not be performed in all coronary artery segments, the
proportion of non-assessable segments was quantified.
Assessment of thoracic images obtained by CT scan-
ning was performed by two investigators (AB and MP)
with documented expertise in radiologic lung imaging.
Pulmonary nodules were evaluated following the guide-
lines for screening of lung cancer published by the Na-
tional Comprehensive Cancer Network (NCCN) [9]. A
nodule was defined as a rounded or irregular opacity in
the lung parenchyma, that was well or poorly defined,
and had a diameter ≤ 3 cm. Also, pulmonary nodules
were labeled as solid opacity, if there was a homogenous
soft-tissue attenuation, or as ground-glass opacity, if
there was a an area of hazy increased lung opacity with
indistinct margins of pulmonary vessels. A positive test
result in CT screening for lung cancer was defined by
the finding of a noncalcified solid nodule ≥6 mm or a
ground-glass nodule> 5 mm [9]. Contrast-to-noise ratio
and signal-to-noise ratio were measured for quantitative
assessment. Radiation doses delivered during CT scans
were collected from patient CT acquisition protocols.
Dose-length product (DLP) was recorded for each pa-
tient. Effective radiation dose (ED) was estimated using
the formula “ED (mSv) ≈DLP x k”, where k is a conver-
sion coefficient specific for adult chests (0.014 mSv/
mGy × cm) [10].
Quantitative coronary angiography
Invasive coronary angiography was accepted as the refer-
ence standard for the purpose of the study. In the week
preceding CT scanning, all patients had left and right
coronary angiography using the transfemoral or transra-
dial approaches. In order to indentify coronary lesions
with a significant (> 70%) stenosis, quantitative coronary
angiography was used. Briefly, two investigators (FP and
GT), blinded to the patients’ characteristics, performed
all measurements independently. Coronary angiograms
were evaluated off-line by means of a system that allows
automated detection of the coronary artery edges (Car-
diovascular Medical System, MEDIS Imaging Systems,
Leiden, The Netherlands) [11]. Prior to coronary angiog-
raphy, a bolus of intracoronary nitroglycerin (200 micro-
grams) was administered. Assessment of coronary wall
morphology was done on angiographic views obtained
after administration of nitroglycerin [12]. Of note, the
investigators took into consideration all coronary lesions
and irregularities that could be visually detected at cor-
onary angiograms. When multiple coronary lesions were
present in a single artery, they were labeled as distinct if
separated by a normal tract of the arterial wall. The per-
cent diameter stenosis was measured in the angiographic
view that showed the most significant narrowing. For
calibration, the catheter tip filled with contrast was used.
This allowed to derive the reference diameter by
interpolation. We measured all coronary segments that
had a diameter > 2 mm showing a stenosis ranging be-
tween 20 and 100% [11]. Assessment of coronary sten-
osis was based on the formula: reference diameter-
minimal lumen diameter/reference diameter × 100.
Statistics
Data analysis included descriptive statistics. All data are
reported as mean ± standard deviation, range, or per-
centage as appropriate. Statistical analysis was computed
using SPSS 18.0.2 (IBM Corporation). The significance
level for differences was set at p ≤ 0.05.
Results
Demographic
Thirty current or former heavy smoker subjects with
chest pain and suspected CAD (20 men, mean age: 66 ±
9 years; range: 59–78 years) underwent simultaneous CT
evaluation of the coronary arteries and the complete
thoracic area (Table 2).
Coronary artery evaluation
At CT scanning, coronary artery segments were judged
to be assessable in 28/30 (93%) patients, as there were
no step artifacts and motion artifacts were uncommon
(3-point score: 0.59 ± 0.55) and did not affect coronary
evaluation. In 2/30 (7%) patients, a total of 8 segments
were judged to be non assessable because of motion ar-
tefacts. Accordingly, per-segment analysis disclosed an
overall 98% assessability (477/485 segments). Coronary
angiography was carried out in 10/30 (33%) patients
who were found to have ≥ 1 coronary stenosis ≥ 70% at
CT scanning (Fig. 2). Noteworthy, the invasive evalu-
ation disclosed that CT scanning had correctly shown
the majority (20/21) of significant (> 70%) coronary sten-
oses. In one patient only, coronary angiography found
an 80% stenosis that was defined as non significant at
CT scanning. Furthermore, cardiac CT showed signifi-
cant in-stent restenosis in one of the patients who had
had percutaneous coronary intervention (Fig. 3).
Pulmonary CT evaluation
Pulmonary nodules were detected in 5 patients. All cases
presented with solid nodules ≥ 6 mm (range: 6–11 mm),
thus requiring to schedule follow-up surveillance CT
thorax. Three other patients presented with solid nod-
ules smaller than 6 mm, which were therefore consid-
ered negative according to National Comprehensive
Cancer Network (NCCN) recommendations. No recur-
rence was found in a patient 5 years after right upper
lobectomy (Fig. 2).
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Table 2 Demographic, history, symptoms and indications to cardiac CT of the study population
No. Heavy
Smoking
Risk factors Indication
to cardiac CT
Cardiac CT
findings
ICA Findings Lung scan
findings
1 Current Hypertension, dyslipidemia High-risk CAD No stenosis Not done None
2 Former Hypertension High-risk CAD LAD prox: 70% stenosis
RCA: 90% stenosis
LAD prox: 80% stenosis
RCA: 95% stenosis
Pulmonary nodule
3 Current – Positive EST No stenosis Not done None
4 Former Hypertension, dyslipidemia,
diabetes
Previous PCI RCA prox: 70% stenosis
RCA mid: 90% stenosis
RCA prox: 80% stenosis
RCA mid: 90% stenosis
None
5 Current – Suspected CAD No stenosis Not done None
6 Former Hypertension, dyslipidemia High-risk CAD LAD mid: 30% stenosis
Cx mid: 90% stenosis
LAD mid: 80% stenosis
Cx mid: 95% stenosis
Pulmonary nodule
7 Current Diabetes High-risk CAD No stenosis Not done None
8 Current Hypertension, dyslipidemia Positive EST LAD prox: 70% stenosis
LAD distal: 70% stenosis
LAD prox: 90% stenosis
LAD distal: 90% stenosis
None
9 Former Diabetes, dyslipidemia Previous PCI Cx prox: 80% stenosis
Cx mid: 90% stenosis
Cx prox: 70% stenosis
Cx mid: 95% stenosis
None
10 Former Hypertension Suspected CAD No stenosis Not done None
11 Current Hypertension, dyslipidemia High-risk CAD No stenosis Not done None
12 Current – Positive EST No stenosis Not done None
13 Former Hypertension, dyslipidemia Suspected CAD No stenosis Not done Pulmonary nodule
14 Current Hypertension, diabetes Suspected CAD No stenosis Not done None
15 Former Hypertension, dyslipidemia Positive EST No stenosis Not done None
16 Former Dyslipidemia Suspected CAD Cx prox: 80% stenosis
Cx mid: 90% stenosis
Cx prox: 70% stenosis
Cx mid: 95% stenosis
None
17 Current Hypertension Previous PCI No stenosis Not done None
18 Current Hypertension, dyslipidemia Positive EST No stenosis Not done None
19 Former Hypertension High-risk CAD LAD prox: 70% stenosis
LAD mid: 70% stenosis
LAD prox: 90% stenosis
LAD mid: 90% stenosis
None
20 Former Diabetes, dyslipidemia Positive EST No stenosis Not done Pulmonary nodule
21 Current Hypertension, dyslipidemia High-risk CAD RCA prox: 80% stenosis
RCA mid: 90% stenosis
RCA prox: 70% stenosis
RCA mid: 95% stenosis
None
22 Current Dyslipidemia High-risk CAD LAD prox: 70% stenosis
OM prox: 90% stenosis
RCA mid: 70% stenosis
LAD prox: 90% stenosis
OM prox: 80% stenosis
RCA mid: 90% stenosis
None
23 Former Hypertension, dyslipidemia High-risk CAD No stenosis Not done None
24 Former Dyslipidemia Suspected CAD No stenosis Not done None
25 Former – Positive EST No stenosis Not done None
26 Current Dyslipidemia Positive EST No stenosis Not done None
27 Current Hypertension Suspected CAD No stenosis Not done None
28 Current Hypertension, dyslipidemia Suspected CAD No stenosis Not done Pulmonary nodule
29 Former Diabetes High-risk CAD No stenosis Not done None
30 Current Hypertension, dyslipidemia Previous PCI RCA prox: In-stent 90%
restenosis
RCA mid: No in-stent
restenosis
RCA distal: No in-stent
restenosis
RCA prox: In-stent 90%
restenosis
RCA mid: No in-stent
restenosis
RCA distal: No in-stent
restenosis
None
CAD Coronary artery disease, COPD Chronic obstructive pulmonary disease, CT Computed tomography, Cx circumflex artery, EST Exercise stress test, F Female, ICA
Invasive coronary angiography, LAD Left anterior descending, M male, No. Number, PCI Percutaneous coronary intervention, RCA Right coronary artery
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Technical characteristics
The mean contrast-to-noise ratio and mean signal-to-
noise ratio were respectively 12.5 ± 4.6 and 12.9 ± 3.3. Ef-
fective dose was 1.3 ± 0.9 mSv (range: 0.8–3.2 mSv).
Noteworthy, no contrast or radiation dose increment
was required with the new protocol as compared to con-
ventional coronary CT protocol.
Discussion
Cardiac CT offers a detailed anatomical assessment of
CAD comparable to invasive coronary angiography [1].
Accordingly, CT coronary angiography has become rap-
idly an effective alternative to the traditional invasive
angiography for screening and evaluating CAD. Indeed,
the new generation of CT scanners has shown to yield
high sensitivity and specificity in detecting angiographic-
ally significant stenoses [3]. Cardiac CT is said to be the
diagnostic test to be preferred for evaluating patients
with stable angina because of its favorable cost/benefit
ratio. According to the guidelines of the National In-
stitute for Health and Care Excellences (NICE), car-
diac CT should be offered to all chest pain patients
in whom CAD is suspected [2]. Especially in case of
a high pre-testing cardiovascular risk profile, cardiac
CT has been shown by randomized controlled trials
to improve detection of CAD when incorporated in
chest pain pathways [13, 14]. Of note, subjects with
high cardiac risk are also current or former smokers
and therefore have also a high-risk of lung cancer. In-
deed, tobacco is a major risk factor for both CAD
Fig. 2 Representative case of coronary artery disease and lung cancer screening. The cardiac CT revealed a significant stenosis of the left anterior
descending coronary artery (left upper panel), which was confirmed at coronary angiography (middle upper panel) and treated with
percutaneous coronary intervention and stenting (right upper panel). Also, the right coronary artery showed a significant long stenosis in the
proximal segment (left lower panel) that was confirmed at coronary angiography (middle lower panel) and treated with percutaneous coronary
intervention and stenting (right lower panel). Ultra-low-dose CT images of the lungs showed a 6 mm pulmonary nodule in the left upper lobe
(arrow, right panel)
Fig. 3 Representative case of follow-up evaluation of a patient with previous percutaneous coronary intervention and previous lung lobectomy. The
cardiac CT revealed a significant in-stent restenosis in the proximal segment of the right coronary artery (left upper panel). Thoracic evaluation showed
no recurrence 5 years after right upper lobectomy (right panel)
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and lung cancer [15, 16], and previous studies have
already ascertained that patients with coronary or
cerebrovascular atherosclerosis are more likely to de-
velop lung cancer [17].
Lung cancer remains the most common cancer in men
and the third most common in women [18]. Early diag-
nosis is an important tool to reduce morbidity and mor-
tality, and CT screening demonstrated a 20% decrease in
the lung cancer mortality for high-risk populations such
as heavy-smokers (> 30 pack/year) from 55 to 74 years
[19, 20]. On the basis of available findings, the US Pre-
ventive Services Task Force now recommends annual
lung cancer screening with ultra-low dose computed
tomography for current and former heavy smokers aged
55 to 80 years.
With this background, there is an increased awareness
that high-risk subjects undergoing imaging for cardio-
vascular conditions could also benefit from lung cancer
screening. Radiation exposure has long been felt as a
major limitation of CT screenings, but recent investiga-
tions have shown that ultra-low-dose CT is safer to
screen high-risk patients [21–23].
Recently, it has been shown that associating a chest
ultra-low-dose CT scan to the cardiac CT protocol for pa-
tients with suspected CAD is useful for lung cancer
screening [5]. Our investigation confirms and extends this
previous finding, as it shows that ultra-lo-dose CT is
effective and safe for simultaneous CAD and lung can-
cer screening. Indeed, we report the first-in-man ap-
plication of a novel ultra-low-dose CT protocol that
allows simultaneous coronary artery and lung screen-
ing. The results obtained in the first series of 30 high-
risk subjects that underwent the novel examination
show that either coronary artery and lung evaluations
were feasible. Noteworthy, no contrast or radiation
dose increment was required as compared to conventional
coronary CT protocol. The novel technique overcomes
the limitation of a double dose of contrast and radiation
usually needed to assess cardiac and lung regions during
two different examinations.
Our study has some limitations. The major limitation
lies on sample size. Even with important preliminary re-
sults, larger studies following up more patients for lon-
ger periods are needed to confirm the role of the novel
ultrafast single protocol for lung cancer screening espe-
cially for reduction in mortality. Some studies have
shown a reduced diagnostic performance to detect pul-
monary nodules for obese patients undergoing fast-
low-dose CT protocol, as higher body mass indexes are
associated with increased image noise [23, 24]. A fur-
ther limitation is constituted by the lack of a control
group. As a consequence, we were unable to compare
the novel ultra-low dose CT protocol with the standard
CT scans.
Conclusions
The new ultrafast-low-dose CT protocol seems to be ef-
fective and safe for simultaneous coronary artery evalu-
ation and lung cancer screening. Such an approach may
enhance the cost-effectiveness of coronary CT in heavy
smokers with suspected CAD. Further studies are
needed to assess the potential of the novel protocol to
reduce cardiovascular and pulmonary morbidity and
mortality in clinical practice.
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